4-Methoxy-3-((4-methylpiperidin-1-yl)methyl)benzaldehyde

Catalog No.: 
ACSEXC402
CAS No.: 
372153-09-8
Molecular Formula: 
C15H21NO2
Molecular Weight: 
247.34
4-Methoxy-3-((4-methylpiperidin-1-yl)methyl)benzaldehyde structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg98%$104.00InquiryInquiry
1g98%$300.00InquiryInquiry
5g98%$1485.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4-Methoxy-3-((4-methylpiperidin-1-yl)methyl)benzaldehyde
IUPAC Name4-methoxy-3-((4-methylpiperidin-1-yl)methyl)benzaldehyde
Molecular FormulaC15H21NO2
Molecular Weight247.34
SMILESO=CC1=CC=C(OC)C(CN2CCC(C)CC2)=C1
InChI KeyYDLSBUYDKUMWHY-UHFFFAOYSA-N
Synonym4-Methoxy-3-[(4-methylpiperidin-1-yl)methyl]-benzaldehyde;Benzaldehyde, 4-methoxy-3-[(4-methyl-1-piperidinyl)methyl]-
CAS No.372153-09-8

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H319
Precautionary Statement(s)
P264-P280-P305+P351+P338-P337+P313

Synthetic Route by SureRoute

1. ACSEXC402 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACSEXC402 route product structure diagram
    ACSEXC402372153-09-8
Inquiry

2. ACSEXC402 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACSEXC402 route product structure diagram
    ACSEXC402372153-09-8
Inquiry

3. ACSEXC402 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACSEXC402 route product structure diagram
    ACSEXC402372153-09-8
Inquiry

Comments (0)